For prescribing information and adverse event reporting, click here

This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

This website has been commissioned by Ipsen UK and is intended for a UK audience.

All materials

Elevating PBC Care – Dr Emma Culver

Primary Biliary Cholangitis (PBC) Video
14:49

This Ipsen sponsored symposium took place at BASL X-tra 2025 led by Dr Emma Culver, Consultant Hepatologist, John Radcliffe Hospital Oxford. Dr Culver talks about personalising the approach to PBC patient care moving to a new treatment paradigm and discusses the latest data related to 2L therapies.

IQV-UK-000365 | May 2025

Explore more Primary Biliary Cholangitis (PBC) Events & Meetings

Explore more Primary Biliary Cholangitis (PBC) Events & Meetings

Browse

To access relevant information about Primary Biliary Cholangitis, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

I am a patient

This section provides information to support patients that have been prescribed IQIRVO®▼ (elafibranor).

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.